← European Medicine Shortage Tracker · all medicines

Docetaxel shortage — availability across Europe

Docetaxel currently has availability issues reported in 4 European registers: Austria, Spain, Greece, Italy.

MEDICALLY REVIEWED
Dr. Chrysoula I. Liakou MD, PhD
Internal Medicine Specialist
Cancer Immunology Researcher
Reviewed 30 July 2026 · next review due 30 January 2027

Shortage  ATC L01CD02 · also listed as: DOCETAXEL · data refreshed 7 August 2026

Key facts

As of 7 August 2026, 4 of the 10 tracked registers list current availability issues for Docetaxel, covering 13 affected product presentations. The longest-running open report was filed in Italy on 2025-10-03 and has now been open for about 10 months. Where agencies state a cause, manufacturing problems lead with 3 of the 4 stated-cause reports, followed by commercial decisions or discontinuation with 1. The furthest expected-resolution date currently on file is 2026-12-14; the earliest is 2026-08-18. Notably, 2 reports have already passed the expected-resolution date without closing — prognoses for this medicine should be read as estimates, not commitments. Momentum is current, not historical: 8 of the open reports were filed within the last 90 days. The issue spread across registers over time rather than at once: Italy reported first (2025-10-03), with Greece following roughly 10 months later — a pattern typical of supply problems cascading between national markets. Registers in Spain, Greece, Italy indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Docetaxel is coded L01CD02 — a medicine acting on antineoplastic and immunomodulating agents — so clinically related products appear under “Related medicines” below.

Resolved Listed in the EMA shortages catalogue — EU-level issue. EMA lists available alternatives — see the EMA record. EMA record ↗
WhereStatus & productsSinceExpected end Reason / alternativesSource
🇪🇺 EU-wide (EMA)Resolved
Taxotere (docetaxel)
2016-05-19Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Stomach Neoplasms;Breast Neoplasms
Alternatives: EMA lists available alternatives — see the EMA record.
register ↗
🇦🇹 AustriaShortage
Docetaxel Accord 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung
+ 1 more products
Docetaxel Accord 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung
2026-06-26register ↗
🇪🇸 SpainShortage
DOCETAXEL GLENMARK 20 MG/1 ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG, 1 vial de 1 ml
+ 3 more products
DOCETAXEL GLENMARK 20 MG/1 ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG, 1 vial de 8 ml
DOCETAXEL HIKMA 160 MG/8 ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG, 1 vial de 8 ml
DOCETAXEL HIKMA 80 MG/4 ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG, 1 vial de 4 ml
2026-02-242026-08-30Existen otros medicamentos con el mismo principio activo y misma vía.
Alternatives: Existe/n otro/s medicamento/s con el mismo principio activo y para la misma vía de administración.
register ↗
🇬🇷 GreeceLimited availability
BTx1VIALx16ML (160MG/16ML)
+ 1 more products
BTx1VIALx8ML (80MG/8ML)
2026-08-242026-12-14PFIZER ΕΛΛΑΣ Α.Ε. Αυξημένη ζήτηση περιεκτικότητας
Alternatives: Εναλλακτικά άλλα σκευάσματα της ίδιας δραστικής, μορφής και
register ↗
🇮🇹 ItalyShortage
DOCETAXEL ACCORD
+ 4 more products
DOCETAXEL ACCORD
DOCETAXEL AUROBINDO
DOCETAXEL AUROBINDO
DOCETAXEL AUROBINDO
2025-10-032026-07-21Problemi regolatori
Alternatives: AIFA: import of a foreign equivalent can be authorised.
register ↗

New register reports per month

2025-10: 12025-11: 02025-12: 02026-01: 02026-02: 12026-03: 02026-04: 22026-05: 32026-06: 32026-07: 02026-08: 22025-102026-08

Full report history (14 register entries)

Every individual register entry for Docetaxel in the tracked sources, newest first — including resolved and discontinued reports.

Reg.ProductStatusReportedExpected endStated reason
🇬🇷 GRBTx1VIALx8ML (80MG/8ML)Limited availability2026-09-242026-12-14PFIZER ΕΛΛΑΣ Α.Ε. Αυξημένη ζήτηση περιεκτικότητας
🇬🇷 GRBTx1VIALx16ML (160MG/16ML)Limited availability2026-08-242026-12-14PFIZER ΕΛΛΑΣ Α.Ε. Αυξημένη ζήτηση περιεκτικότητας
🇮🇹 ITDOCETAXEL AUROBINDOShortage2026-08-12Problemi produttivi
🇪🇸 ESDOCETAXEL HIKMA 80 MG/4 ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFShortage2026-06-292026-08-18Existen otros medicamentos con los mismos principios activos
🇦🇹 ATDocetaxel Accord 160 mg/8 ml Konzentrat zur Herstellung einer InfusionShortage2026-06-26
🇦🇹 ATDocetaxel Accord 80 mg/4 ml Konzentrat zur Herstellung einer InfusionsShortage2026-06-26
🇪🇸 ESDOCETAXEL HIKMA 160 MG/8 ML CONCENTRADO PARA SOLUCION PARA PERFUSION EShortage2026-05-27Existen otros medicamentos con el mismo principio activo y m
🇪🇸 ESDOCETAXEL GLENMARK 20 MG/1 ML CONCENTRADO PARA SOLUCION PARA PERFUSIONShortage2026-05-202026-08-30Existen otros medicamentos con el mismo principio activo y m
🇮🇹 ITDOCETAXEL ACCORDShortage2026-05-06Problemi regolatori
🇮🇹 ITDOCETAXEL AUROBINDOShortage2026-04-272026-07-21Problemi produttivi: distribuzione contingentata
🇮🇹 ITDOCETAXEL ACCORDShortage2026-04-24Motivi commerciali
🇪🇸 ESDOCETAXEL GLENMARK 20 MG/1 ML CONCENTRADO PARA SOLUCION PARA PERFUSIONShortage2026-02-242026-08-30Existen otros medicamentos con el mismo principio activo y m
🇮🇹 ITDOCETAXEL AUROBINDOShortage2025-10-032026-07-21Problemi produttivi: distribuzione contingentata
🇪🇺 EUTaxotere (docetaxel)Resolved2016-05-19Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adeno

Frequently asked

Is Docetaxel currently in shortage in Europe?

Yes. As of 7 August 2026, availability issues are reported in: Austria, Spain, Greece, Italy. Availability is national — a shortage in one country does not mean it is short everywhere.

When is the Docetaxel shortage expected to end?

Agency prognoses on file range from 2026-08-18 to 2026-12-14. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.

Are there alternatives to Docetaxel?

11 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.

Where does this Docetaxel availability data come from?

Directly from the official medicines-agency registers that list Docetaxel: BASG (Austria), AEMPS CIMA (Spain), EMA shortages catalogue (EU), EOF limited-availability list (Greece), AIFA (Italy). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.

Related medicines (same ATC class)

Embed this tracker

Pharmacies, patient sites and newsrooms are welcome to embed the live status of Docetaxel — free, with attribution. Copy this snippet:

<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/docetaxel/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Docetaxel availability in Europe"></iframe>
<p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/docetaxel/">Docetaxel shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>
Cite: “Docetaxel: availability status across 5 European registers — European Medicine Shortage Tracker (MobiDoctor), 7 August 2026.” Link this page and the agency record. Statuses come from the linked official registers and can change daily.